Drug Trial Radar · NCT03192345
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Jun 9, 2017
Primary completion
Dec 21, 2021
Study completion Jan 17, 2022
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: Dose escalation (Part 1) Part 1A (SAR439459 monotherapy) * To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors. Part 1B (SAR439459 and cemiplimab combination therapy) * To determine the MTD and/or MAD of SAR439459 administered intravenously in combination with cemiplimab administered intravenously in adult patients with advanced solid tumors. Dose expansion (Part 2) Part 2A (SAR439459 monotherapy) * To determine optimal dose of SAR439459 administered intravenously in adult patients with advanced melanoma who have failed a prior therapy based on anti-PD-1 (programmed cell death-1) or anti-PD-L1. Part 2B (SAR439459 and cemiplimab combination therapy) * To determine the objective response rate (ORR) of SAR439459 in combination with cemiplimab in adult patients with selected advanced solid tumors by evaluation of antitumor response according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). Secondary Objectives: * Pharmacokinetic (PK) profile SAR439459 monotherapy and combined with cemiplimab, PK profile of cemiplimab combined with SAR439459. * Immunogenicity of SAR439459 monotherapy and combined with cemiplimab. Dose escalation (Part 1) * Overall safety/tolerability profile of SAR439459 monotherapy and combined with cemiplimab. * Preliminary recommended phase 2 dose (pRP2D) of SAR439459 as monotherapy or combined with cemiplimab. Dose expansion (Part 2) * Progression free survival (PFS), time to progression (TTP), ORR, and safety of SAR439459 as monotherapy and PFS, TTP, duration of response (DOR), disease control rate (DCR) and safety in combination with cemiplimab. * To confirm the optimal dose of SAR439459 administered in combination with cemiplimab.
Conditions
- Malignant Solid Tumor
Interventions
SAR439459Biological
Pharmaceutical form: powder for solution for infusion Route of administration: intravenous infusion
Cemiplimab REGN2810Drug
Pharmaceutical form: solution for infusion Route of administration: intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: Through the end of 1 or 2 cycles, total duration up to 6 weeks (for Part 1A each cycle is 2 weeks; for Part 1B each cycle is 2 or 3 weeks)
- Objective Response Rate (ORR) for Part 2BTime frame: Continuous throughout study assessment (up to approximately 1 year)
Locations
34 sites in 13 countries. Site status is shown where the registry gives one.
The University of Kansas Clinical Research Center Site Number : 8400004
Fairway, Kansas
Massachusetts General Hospital Site Number : 8400001
Boston, Massachusetts
Dana Farber Cancer Institute Site Number : 8400101
Boston, Massachusetts
Duke University Medical Center Site Number : 8400008
Durham, North Carolina
Tennessee Oncology, PLLC Site Number : 8400006
Nashville, Tennessee
Mary Crowley Cancer Research Center Site Number : 8400003
Dallas, Texas
Investigational Site Number : 0360002
Heidelberg West, Victoria, Australia
Investigational Site Number : 0360001
Melbourne, Victoria, Australia
Investigational Site Number : 0560001
Leuven, Belgium
Investigational Site Number : 1240003
Calgary, Alberta, Canada
Investigational Site Number : 1240001
Toronto, Ontario, Canada
Investigational Site Number : 1240002
Montreal, Quebec, Canada
Investigational Site Number : 2330001
Tallinn, Estonia
Investigational Site Number : 2500002
Marseille, France
Investigational Site Number : 2500003
Nantes, France
Investigational Site Number : 2500005
Nantes, France
Investigational Site Number : 2500001
Villejuif, France
Investigational Site Number : 2760001
Essen, Germany
Investigational Site Number : 2760003
Hanover, Germany
Investigational Site Number : 3800001
Milan, Italy
Investigational Site Number : 3800002
Milan, Italy
Investigational Site Number : 3800003
Rozzano, Milano, Italy
Investigational Site Number : 5280001
Rotterdam, Netherlands
Investigational Site Number : 5280002
Utrecht, Netherlands
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 7240002
Barcelona, Barcelona [Barcelona], Spain
Investigational Site Number : 7240001
Barcelona, Barcelona [Barcelona], Spain
Investigational Site Number : 7240003
Madrid / Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7240004
Madrid / Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 7240005
Pamplona, Navarre, Spain
Investigational Site Number : 1580002
Tainan, Taiwan
Investigational Site Number : 8260001
Glasgow, Central Bedfordshire, United Kingdom
Investigational Site Number : 8260002
Cardiff, Vale of Glamorgan, the, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.